Abstract
This market analysis provides a unique examination of five key oncology
therapy areas: breast cancer, non-small cell lung cancer, colorectal cancer,
prostate cancer, renal cancer.
Understand the prospects for this US$47.2 billion market
Unique market share, sales forecasts by product to 2012
A comprehensive examination of five major oncology areas:
- Breast cancer: Focusing on the changes in the gold standard, the
impact of novel therapies on treatment and the new drugs in development.
- Non-small cell lung cancer: Focusing on the launch of novel
therapies into the arena; are they dramatically changing the way NSCLC is
treated?
- Colorectal cancer: Focusing on the evolution of new treatment
regimes, the development of new formulations and advances in cancer vaccines.
- Prostate cancer: Focusing on current hormonal therapies, the
treatment of HRPCA and improvements in screening.
- Renal cancer: With up to 9 new launches by 2012, renal cancer is in
an exciting stage of development.
Critical competitive evaluation and scoring of current and upcoming products
For each therapy area the report provides:
THE FACTS
- Risk factors, how the disease affects patients, diagnosis and stages of
the disease
PATIENT STATISTICS
- Prevalence in the US, Europe and Japan
- Diagnosis and treatment rates
THE MARKET
- Global cancer market (all types)
- Global cancer market split by US, Europe and Japan (by specific cancer)
- The companies - market share 2006 and 2012
CURRENT TREATMENTS
- Interventions by type
- Unique five point competitive assessment of current therapies and
companies involved
- Sales forecasts by product 2006A-2012E
R&D: DRUGS IN PHASE II/III
- Focus on new classes of drugs and the companies involved
- Unique competitive assessment of current therapies and companies involved
- Sales forecasts by product from year of launch to 2012
COMPETITOR ANALYSIS - PRODUCTS & COMPANIES
- Winners and losers in the future
EXTENSIVE APPENDICES
- Statistics on key areas such as patient population, launch probability
|